Federal agents arrested the treasurer of a Canadian healthcare company, accusing him of running a nine-year scheme to smuggle prescription drugs into the United States.
Quick Take
- John Thomas Howard, treasurer and director of CANARX, was arrested on smuggling-related charges tied to drug imports from 2017 to 2026.
- A Food and Drug Administration (FDA) agent’s affidavit says there is probable cause that CANARX illegally imported or caused the illegal importation of prescription drugs.
- CANARX’s lawyer says the Howards deny every charge and expect to be cleared in court.
- The case reopens a decades-old fight over whether Americans can legally buy cheaper medicine from Canada.
What Federal Agents Say Happened
Court records filed this week accuse CANARX’s top leadership of knowingly bringing prescription drugs into the country outside legal channels for years. Dustin Dobbs, a special agent with the FDA’s Office of Criminal Investigations, wrote in his affidavit that evidence supports probable cause that the company illegally imported drugs between February 2017 and April 2026. Howard was taken into custody on smuggling-related charges, and a second CANARX executive faces similar allegations.
This is not the government’s first run-in with CANARX. Back in 2019, the FDA sent the company a warning letter accusing it of causing unapproved and misbranded drugs to enter interstate commerce. In 2023, the agency seized medication CANARX had shipped to a U.S. patient, telling the person in an email the product was potentially counterfeit or mislabeled and that they didn’t qualify to receive it.
The Company’s Response to the Charges
CANARX general counsel Joseph Morris told CNBC that Howards denies all the charges, will fight them vigorously, and expects to be vindicated. He described CANARX not as an online pharmacy but as a broker connecting American patients with licensed, brick-and-mortar pharmacies in Canada, the United Kingdom, and Australia. He said those “tier one” countries hold drug standards similar to America’s own.
U.S. authorities are accusing the two top officials of a Canadian company of operating a long-running scheme to illegally import prescription drugs into the U.S., according to court records.
Read more: https://t.co/Pqj6GA53Hz pic.twitter.com/qEx2IGC5uU
— CNBC (@CNBC) November 12, 2026
Morris also said the company built safety checks into its process to confirm medicines were genuine, came from recognized manufacturers, and matched what a patient’s own doctor had prescribed. He added that CANARX contracts directly with each patient, so no employer or government forces anyone to accept a foreign-sourced drug. After the 2019 warning letter, the company agreed to stop importing medications that require a doctor’s hands-on administration, even though it insisted it had never misled anyone.
A Legal Gray Zone Decades in the Making
This fight didn’t start with CANARX, and it won’t end with it. Federal law has long banned importing unapproved drugs, yet regulators have quietly tolerated personal, small-scale importation for years while rarely cracking down hard on it. Congress even passed a law back in 2003 allowing commercial drug importation from Canada, but no administration actually activated that pathway until 2020. That left a confusing gap between what’s written in law and what’s actually enforced.
Cities, school districts, and employers have used Canadian drug programs like CANARX’s for years, betting that lower prices were worth the legal risk. Inspections by border authorities have found a large share of foreign drug shipments violate federal rules in some way, which is exactly the kind of statistic prosecutors point to when building cases like this one. Supporters of importation counter that affordability, not danger, is the real story driving patients and employers across the border in the first place.
What happens next matters well beyond CANARX’s offices. Thousands of American patients and dozens of employer health plans have relied on similar Canadian drug arrangements to cut costs on everything from insulin to cancer treatments. If prosecutors win this case, it could chill the whole cross-border drug industry overnight. An arrest is only an allegation, not a conviction, and the Howards are entitled to make their case in court. But the broader question of whether American patients should be free to buy safe, cheaper medicine from trusted allies abroad isn’t going away anytime soon.
Sources:
cnbc.com, tradersunion.com, fda.gov, mcbath.house.gov, statnews.com
